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P ediatric lymphoblastic lymphoma (LBL) consists of precursor B-cell and precursor T-cell LBL.  
Pediatric patients with LBL are usually treated using the 
standard treatment strategy for pediatric acute lympho-
blastic leukemia (ALL),  since the two diseases are bio-
logically similar; children treated with this approach 
have a favorable outcome [1-3].  The exact same proto-
col [1-4] is used for both conditions — namely,  chemo-
therapy consisting mainly of prednisolone,  vincristine,  
and L-asparaginase.  The protocol involves a 4-week 
remission-induction phase with an anthracycline drug 
and an alkylating agent.  Drugs not used for remission- 
induction are then added to an early intensive phase.  
After a central nervous system (CNS) prophylaxis phase 
(high-dose methotrexate 3 × 3 g/m2),  patients are tran-
sitioned to a maintenance phase.  The therapeutic regi-
men adopted for the current trial uses this ALL-type 
basic framework.  
Although the standard treatment described above is 
generally used for pediatric patients with localized LBL,  
the optimum treatment remains to be determined due 
to the small number of patients.  Nonetheless,  it is 
apparent that adequate therapy for patients with stage 
I/II pediatric LBL is an ALL-type therapy with a certain 
level of therapeutic intensity lower than that required 
for stage III/IV disease.  In previous clinical trials [1 , 5],  
patients with limited stage LBL have received treatment 
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of the same intensity as patients with advanced stage 
LBL.  It is presumed that the intensity of chemotherapy 
for limited stage LBL can be attenuated,  since event-
free survival was obtained in all cases of limited stage 
LBL in the literature.
Although the Berlin-Frankfurt-Munster (BFM) 90 
protocol [5] has been considered as a standard therapy,  
it has a number of problems when treating patients with 
stage I/II pediatric LBL.  Specifically,  even though the 
protocol achieves a good prognosis for children with 
limited stage disease,  the regimen is too intense and the 
cumulative doses of both anthracycline and alkylating 
agents — known to cause late complications — are high.  
To resolve these problems,  we planned a clinical trial to 
examine the efficacy and safety of a modified BFM reg-
imen.
Endpoints
Primary endpoint. The primary outcome is the 
3-year event-free survival (EFS) rate.
Secondary endpoints. The secondary endpoints 
are (1) occurrence rates of adverse events of grade 3 or 
higher,  according to the National Cancer Institute’s 
Common Toxicity Criteria; and (2) the 3-year overall 
survival rate.  
Eligibility Criteria
Inclusion criteria. The inclusion criteria for the 
trial are as follows.  (1) Newly diagnosed with stage I/II 
non-Hodgkin’s lymphoma — either precursor T-cell LBL 
or precursor B-cell LBL — based on the World Health 
Organization’s categorization [6]; (2) Younger than 
18 years old at the time of diagnosis; (3) Untreated at 
the time of trial registration; (4) Able to be followed up 
for at least 3 years after initiating therapy; (5) Provision 
of written informed consent to participate in the trial,  
obtained from a legal representative.
Exclusion criteria. The exclusion criteria for the 
trial are as follows.  (1) Down syndrome; (2) History of 
malignant tumor,  hematopoietic stem-cell transplanta-
tion or organ transplantation; (3) History of congenital 
or acquired immunodeficiency; (4) Assessed by the 
attending physician as being unsuitable for the trial.  
Methods
Study design. This is a phase IIb,  multicenter 
trial.  The subjects are patients categorized as having 
stage I/II pediatric LBL according to the Murphy stag-
ing system [7].  Fig. 1 provides an overview of the treat-
ment protocol.  This study has been registered in the 
Clinical Trial Registry (University Hospital Medical 
Information Network Clinical Trials Registry [UMIN-
CTR]) under no.  UMIN000002213).
Treatment methods. A schema of the treatment 
regimen is shown in Fig. 2.  The following modifications 
were made to the standard therapy (the BFM90 proto-
col) for stage I/II [5]:
(1) In the remission-induction phase,  daunorubicin 
will be administered only twice (reduced from 
4 times); this drug will be administered again in 
the re-induction phase.  Because this population
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Fig. 1　 Overview of the study treatment.  After enrolling subjects 
in this study,  we will perform a 2-year modiﬁed BFM-type multidrug 
combination chemotherapy.
has a favorable prognosis,  the dau-
norubicin administrations were 
divided to effectively create a re-in-
duction phase without increasing 
the total anthracycline dose given.
(2)  In the remission-induction phase,  
cyclophosphamide was moved to 
day 1.  The cyclophosphamide 
doses usually given on days 36 
and 64 were reduced to 500 mg/
m2 and will be given on days 29 
and 43.  This will allow mainte-
nance of the total cyclophospha-
mide dose so as to maintain ther-
apeutic intensity,  and so that 
patients can proceed directly to 
the early intensive phase,  without 
an interval.
(3)  In the remission-induction phase,  
the dosage of L-asparaginase was 
changed from 10,000 U/m2 ×  
8 times to 6,000 U/m2 × 9 times.  
This will avoid the administration 
of L-asparaginase and vincristine 
on the same day.
(4)  The number of total cytarabine 
administrations was reduced,  
from 16 to 12 times.  This will 
reduce the duration of neutrope-
nia.
(5)  In the CNS-prophylaxis phase the 
dose per administration of high-
dose methotrexate was reduced 
from 5 g/m2 to 3 g/m2,  and the 
number of doses was reduced 
from 4 to 3.  This will shorten the 
CNS-prophylaxis phase,  as the 
standard 2-month period was 
considered too long [8 , 9].
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PSL 60mg/m2(capped at 80mg)
VCR 1.5mg/m2(capped at 2mg)
CPA 1.0g/m2
DNR 30mg/m2(capped at 45mg)
L-ASP 6,000U/m2
DIT MTX＋HDC
PSL 60mg/m2
CPA 1.0g/m2
Ara-C 75mg/m2
6-MP 60mg/m2
DIT MTX＋HDC
HD-MTX 3.0g/m2
DIT MTX＋HDC
PSL 60mg/m2(capped at 80mg)
VCR 1.5mg/m2(capped at 2mg)
CPA 1.0g/m2
DNR 30mg/m2(capped at 45mg)
L-ASP 6,000U/m2
DIT MTX＋HDC
MTX 20mg/m2
6-MP 60mg/m2
Fig. 2　 Schema of the treatment regimen.  The treat-
ment regimen consists of a basic backbone of BFM-type 
ALL treatment and contains a re-introduction phase.  A 
4-week remission induction phase consisting of PSL,  
VCR,  CPA,  DNR and L-ASP,  an early consolidation 
phase consisting of 6-MP,  CPA and Ara-C,  a CNS 
prophylactic phase with high-dose MTX,  a 2-week 
re-induction phase,  and maintenance therapy by oral 
administration of 6-MP and MTX will be carried out.
(6)  A re-induction phase was newly introduced.  The 
re-induction phase will consist of 5 drugs: pred-
nisolone,  vincristine,  cyclophosphamide,  dauno-
rubicin,  and L-asparaginase.  This phase will 
address the treatment of patients with large tumors.
(7)  In regard to the number of intrathecal injections and 
drugs,  instead of 9 solitary intraspinal injections of 
methotrexate,  7 intraspinal injections comprising 
2 drugs (methotrexate and cytarabine) will be given.
(8)  In the maintenance phase,  patients will receive daily 
mercaptopurine (starting at 60 mg/m2 and adjust-
ing based on the white blood cell (WBC) count) and 
weekly methotrexate (starting at 20 mg/m2 and 
adjusting based on the WBC count).
Statistical Considerations
Sample size. Although studies from Japan and 
overseas have indicated that patients with stage I/II 
pediatric LBL have favorable prognosis,  an EFS rate that 
could serve as a clear criterion has not been published 
due to the small number of cases in these studies.  
Therefore,  in this trial we set an expected efficacy rate 
of 95% and a threshold efficacy rate of 80% for 3-year 
EFS.  Because this is a single arm trial,  if the type-1 
error is set to 0.05 and the type-2 error is set to 0.2,  the 
number of cases needed is 42.  Assuming that 10% of 
cases will be disqualified,  48 cases are needed.  Eight 
cases are expected to be registered in Japan per year,  so 
a 6-year registration period is required to obtain the 
necessary number of cases to examine the aforemen-
tioned statistical hypothesis.
Statistical analysis. The primary endpoint 
(3-year EFS rate) will be evaluated using the Kaplan-
Meier method.  We will calculate 3-year EFS rate point 
estimates and 95% confidence intervals using 
Greenwood’s formula.  If the upper limit of the 95% 
confidence interval does not reach the expected efficacy 
rate (95%),  therapy with the protocol regimen will be 
considered ineffective.  In principle,  the occurrence rate 
of adverse events will be calculated using a binomial 
distribution for point estimates and 95% confidence 
intervals,  assessed for the items requiring regular mon-
itoring.  The Kaplan-Meier method will be used to eval-
uate the 3-year overall survival rate.
Discussion
It is expected that this trial will help to establish an 
effective and safer standard therapy for patients with 
stage I/II pediatric LBL in Japan.  If this trial confirms 
the protocol’s efficacy and safety,  its results can be used 
to establish an optimal therapy with less toxicity.
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